Virtual Library

Start Your Search

Robert Schouten



Author of

  • +

    P2.04 - Immuno-oncology (ID 167)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Immuno-oncology
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.04-83 - Long-Term Follow-Up Compassionate Use Program Nivolumab in NSCLC (ID 904)

      10:15 - 18:15  |  Author(s): Robert Schouten

      • Abstract

      Background

      Background: From August 2015 until March 2016, patients with NSCLC were treated in the Early Access Program (EAP) or commercially available nivolumab. Here, we report the long term survival figures for this Real Life treatment (early data were presented at WCLC in 2016). Currently, the median follow-up is 3 years for the patients treated in the EAP, and 2.5 years for the patients that have been treated with commercially available nivolumab. We address open questions of the efficacy of nivolumab in real life on special subgroups (brain mets, elderly, ECOG, smoking, platinum sensitivity) with regards to OS.

      Method

      Methods: A prospective follow up of 248 pts was performed with respect to the above mentioned subgroups using Kaplan Meier curves and Cox proportional hazards regression.

      Result

      Results: Median age 63 (29-84); 55% male; 81% (ex)-smoker; 67% adeno, 22% squamous and 11% mixed type carcinoma; PS 0-1: 84%; PS 2-3: 16%; brain mets 23%.
      Overall survival in the whole group was 17% at 3 years. For the subgroups, the PS 2-3 vs 0-1 showed a HR of 1.77 (p=0.0023); Platinum sensitive vs resistant showed a HR of 0.55 (p=0.00032): (Ex) Smoker vs never smoker showed a HR of 0.62 (p=0.007) and no difference was observed between Squamous vs Non-squamous or for patients who initially presented with or without brain mets.

      Conclusion

      Conclusions: These data confirm the activity of nivolumab in second line treatment outside of a reported study. The 17% 3 yrs survival is exactly in line with the pooled data from the Checkmate 017/057 study (Vokes et al. Ann Oncol 32018, 29;9590-65). Long term efficacy of this checkpoint inhibitor is confirmed. Good performance status, smoking, non-squamous carcinoma and platinum sensitive tumors are positive predictive factors.